EcoR1 Capital
EcoR1 Capital reported 34 stocks worth $2B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ZYME (29.9%), ANAB (19.5%) and CGON (6.5%). Compared with Q2 2026, the fund opened new positions in ANRO, ATTO and ADRX, added to CGON, ETON and ERAS, trimmed ORIC, BBOT and ZURA and sold out of LEGN, MBX and RLAY.
Latest filing: what EcoR1 Capital did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() ZYME Zymeworks Inc | $608M | 29.9% | 23M | No change | 8 of 8 | |
| 2 | ![]() ANAB Anaptysbio Inc | $396M | 19.5% | 7.9M | No change | 8 of 8 | |
| 3 | ![]() CGON CG Oncology Inc | $133M | 6.5% | 1.9M | +378K (+25%) | 4 of 8 | |
| 4 | ![]() ETON Eton Pharmaceuticals Inc | $127M | 6.3% | 2.5M | +299K (+14%) | 8 of 8 | |
| 5 | ![]() TRAX First Tracks Biotherapeutics | $113M | 5.5% | 3.2M | No change | 2 of 8 | |
| 6 | ![]() AKTS Aktis Oncology Inc | $93.9M | 4.6% | 4.8M | No change | 3 of 8 | |
| 7 | ![]() CRSP Crispr Therapeutics | $76.9M | 3.8% | 1.4M | No change | 8 of 8 | |
| 8 | ![]() ANRO Alto Neuroscience Inc | $57M | 2.8% | 2.2M | New position | 1 of 8 | |
| 9 | ![]() LKFT Galapagos NV | $49.4M | 2.4% | 1.7M | No change | 8 of 8 | |
| 10 | ![]() ERAS Erasca Inc | $43.2M | 2.1% | 3M | +2.6M (+794%) | 3 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() LEGN Legend Biotech Corp | $23.1M | 800K |
![]() MBX Mbx Biosciences Inc | $21.4M | 389K |
![]() RLAY Relay Therapeutics Inc | $13.1M | 698K |
![]() PHAT Phathom Pharmaceuticals Inc | $6.8M | 625K |
![]() MREO Mereo Biopharma Group PLC | $318K | 1M |
🔒 Free account: see all 6.
Options
valued at the underlying sharesReported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →EcoR1 Capital 13F FAQ
What does EcoR1 Capital own?
EcoR1 Capital reported 34 stocks worth $2B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ZYME (29.9%), ANAB (19.5%) and CGON (6.5%). The table above lists every position in the filing (the top 10 without an account).
What did EcoR1 Capital buy and sell in Q3 2026?
Compared with Q2 2026: 9 new positions, 8 added to, 3 trimmed and 6 sold out. New positions include ANRO, ATTO and ADRX. It sold all of LEGN, MBX and RLAY.
When will EcoR1 Capital file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is EcoR1 Capital's portfolio worth?
The Q3 2026 filing reports $2B in US stocks ($2.3B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.
























